Details for Patent: 8,906,410

Which drugs does patent 8,906,410 protect, and when does it expire?

Patent 8,906,410 protects RAYALDEE and is included in one NDA.

This patent has twenty-eight patent family members in thirteen countries.

Summary for Patent: 8,906,410

Title:	Oral dosage form of 25-hydroxyvitamin D
Abstract:	Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D.sub.2, 25-hydroxyvitamin D.sub.3, or a combination of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D.sub.2, 25-hydroxyvitamin D.sub.3, or a combination of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3.
Inventor(s):	Bishop; Charles W. (Mount Horeb, WI), Crawford; Keith H. (Highlands Ranch, CO), Messner; Eric J. (Lake Forest, IL)
Assignee:	Opko Health, Inc. (N/A)
Application Number:	13/848,982
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,906,410

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes			Y

International Family Members for US Patent 8,906,410

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2640094
Canada	2882048
Cyprus	1118017